Roche and Zealand Pharma Announce Positive Phase 2 Data for Obesity Drug Petrelintide

Key Facts

1Roche and Zealand Pharma released topline Phase 2 data for their amylin analogue petrelintide.

Roche Holding AG and Zealand Pharma released topline Phase 2 data for their amylin analogue petrelintide, a candidate for weight management. Seeking Alpha reported that the ZUPREME-2 trial, which enrolled 220 individuals who are overweight or obese, demonstrated that petrelintide achieved significant weight reduction and A1C improvement compared to a placebo.

The companies are developing petrelintide as a potential alternative to GLP-1 therapies in the high-growth obesity drug sector. Regarding market performance, RHHVF closed at $431.7 on October 7, 2026, after trading between a low of $425.26 and a high of $441.98 during that session.